Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7559MR)

This product GTTS-WQ7559MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7559MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6148MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ15273MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ2053MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10552MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ6078MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ6535MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ7898MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ15694MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW